am 251 and alprazolam
am 251 has been researched along with alprazolam in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| García-Gutiérrez, MS; Manzanares, J | 1 |
| Aguiar, DC; Gobira, PH; Moreira, FA | 1 |
Other Studies
2 other study(ies) available for am 251 and alprazolam
| Article | Year |
|---|---|
The cannabinoid CB1 receptor is involved in the anxiolytic, sedative and amnesic actions of benzodiazepines.
Topics: Alprazolam; Amnesia; Amygdala; Animals; Anti-Anxiety Agents; Anxiety; Avoidance Learning; Behavior, Animal; Benzodiazepines; CA1 Region, Hippocampal; GTP-Binding Protein gamma Subunits; Hypnotics and Sedatives; Male; Mice; Mice, Inbred ICR; Nervous System Diseases; Organ Specificity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Severity of Illness Index | 2010 |
Effects of compounds that interfere with the endocannabinoid system on behaviors predictive of anxiolytic and panicolytic activities in the elevated T-maze.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Behavior, Animal; Benzamides; Benzodiazepines; Benzoxazines; Carbamates; Endocannabinoids; Locomotion; Male; Maze Learning; Morpholines; Naphthalenes; Panic; Piperidines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1 | 2013 |